D8.2 Application of IDMP in Drug Labelling and Drug Information, in Clinical Decision Support and in Quality Assurance of Clinical Data
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2024
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901753257000960 |
|---|---|
| author | UNICOM Consortium |
| author_facet | UNICOM Consortium |
| contents | <p>In this deliverable we discuss the final results of task T8.1 on IDMP and Clinical care.<br>We explore what IDMP can mean for quality of care in pharmacotherapy, and how it can be integrated in clinical decision support systems.<br>First, we discuss the grouping of active substances and medicinal products into pharmaco-therapeutic groups, with the ATC classification, SNOMED-CT and RxNorm, Classifications of international Medicinal product Dictionaries, the Standardised Drug Groups of the Uppsala Monitoring Centre, and a classification for medical education and patient information.<br>Then, we describe a methodology for linking International Drug Classifications to National Medicinal Products, from national medicinal product packs to global pharmaceutical product, to the ATC level V class, and to Clinical Classifications.<br>In a next chapter, we describe the initiatives to produce meaningful sets of medicinal products, standardised to IDMP, such as the UNICOM Pilot Product List, the UFIS Database, the T6.1 UNICOM FHIR Server, and the Minimal Data Set, containing all medicinal products for 4 substances from 10 countries. The objective of this description is to illustrate the importance of having IDMP-compliant data for demonstration purposes.<br>Finally, the use of this Minimal Data Set in the Patient Facing APP and in decision support systems is discussed.<br>This work concludes by stating that the implementation of the ISO/CEN standards will bring precision and robustness to the application of decision rules, expressed in general drug class statements, in the national Medicinal Product Dictionaries, allowing decision support systems to cross the borders of the member states in Europe in a feasible way.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17725353 |
| institution | Zenodo |
| language | |
| publishDate | 2024 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | D8.2 Application of IDMP in Drug Labelling and Drug Information, in Clinical Decision Support and in Quality Assurance of Clinical Data UNICOM Consortium IDMP Drug Labelling Clinical Decision Support Quality Assurance of Clinical Data <p>In this deliverable we discuss the final results of task T8.1 on IDMP and Clinical care.<br>We explore what IDMP can mean for quality of care in pharmacotherapy, and how it can be integrated in clinical decision support systems.<br>First, we discuss the grouping of active substances and medicinal products into pharmaco-therapeutic groups, with the ATC classification, SNOMED-CT and RxNorm, Classifications of international Medicinal product Dictionaries, the Standardised Drug Groups of the Uppsala Monitoring Centre, and a classification for medical education and patient information.<br>Then, we describe a methodology for linking International Drug Classifications to National Medicinal Products, from national medicinal product packs to global pharmaceutical product, to the ATC level V class, and to Clinical Classifications.<br>In a next chapter, we describe the initiatives to produce meaningful sets of medicinal products, standardised to IDMP, such as the UNICOM Pilot Product List, the UFIS Database, the T6.1 UNICOM FHIR Server, and the Minimal Data Set, containing all medicinal products for 4 substances from 10 countries. The objective of this description is to illustrate the importance of having IDMP-compliant data for demonstration purposes.<br>Finally, the use of this Minimal Data Set in the Patient Facing APP and in decision support systems is discussed.<br>This work concludes by stating that the implementation of the ISO/CEN standards will bring precision and robustness to the application of decision rules, expressed in general drug class statements, in the national Medicinal Product Dictionaries, allowing decision support systems to cross the borders of the member states in Europe in a feasible way.</p> |
| title | D8.2 Application of IDMP in Drug Labelling and Drug Information, in Clinical Decision Support and in Quality Assurance of Clinical Data |
| topic | IDMP Drug Labelling Clinical Decision Support Quality Assurance of Clinical Data |
| url | https://doi.org/10.5281/zenodo.17725353 |